Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy

Launched by XIJING HOSPITAL · Aug 3, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating the effects of a medication called minocycline on patients who have suffered an ischemic stroke and are undergoing a procedure called mechanical thrombectomy to restore blood flow to the brain. Minocycline is believed to help protect the brain by reducing damage and inflammation during and after the stroke. The study aims to enroll 180 participants aged 18 to 85 who have experienced a specific type of stroke and meet certain criteria, such as having a significant blockage in a blood vessel supplying the brain.

If you or a family member participate in this trial, you can expect to receive minocycline alongside standard treatment after the thrombectomy. Researchers will monitor your health and recovery for three months to see if minocycline helps improve outcomes after the stroke. It's important to note that there are specific health conditions that could prevent someone from participating, so discussing eligibility with your doctor is essential. Overall, this study is important for understanding how minocycline may enhance recovery after a stroke and improve patients' quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with acute cerebral infarction of anterior circulation accompanied by large vessel occlusion;
• • 2. Age 18-85 years old;
• • 3. The time of onset ≤ 6 hours or ≤ 24 hours suitable for mechanical thrombectomy determined by multimodal imaging;
• • 4. The time of onset 6-24 hours, DWI shows an infarct volume less than 1/3 of the MCA blood supply area; the time of onset ≤ 6 hours, the ASPECTS(Alberta Stroke Program Early CT Score) is ≥6;
• • 5. Preoperative NIHSS score ranges from 6 to 30 points;
• • 6. Sign the informed consent form;
• Exclusion Criteria:
• • 1. There are contraindications for mechanical thrombectomy;
• • 2. No revascularization therapy was performed during the operation or the TICI score after revascularization therapy was less than 2b;
• • 3. There are other major central nervous system diseases, such as brain injury, brain tumor, multiple sclerosis, etc;
• • 4. There is evidence that the patient has bacterial endocarditis, aortic dissection, arteritis or venous cerebral infarction;
• • 5. Renal insufficiency or hepatic insufficiency (serum creatinine \>2.0 mg/dL or 180 µmol/L; liver function greater than 3 times the normal value);
• • 6. Known history of congestive heart failure (requiring dietary or medication changes or hospitalization) within 6 months, or myocardial infarction within 6 months;
• • 7. There is evidence of any other life-threatening or severe diseases that may hinder the completion of the 3-month follow-up and affect the evaluation of the results;
• • 8. Pre-existing neurological deficits or history of dementia;
• • 9. There are infectious diseases that require antibiotic treatment before the disease;
• • 10. Allergic to tetracyclines or unable to take minocycline for other reasons;
• • 11. Minocycline could not be given within 1 hour after recanalization;
• • 12. Pregnant patients;
• • 13. Participated in another clinical trial within 30 days before inclusion in the study.
• • 14. Refuse to sign the informed consent form.